|
1
|
Duarte S, Carle G, Faneca H, de Lima MC
and Pierrefite-Carle V: Suicide gene therapy in cancer: Where do we
stand now? Cancer Lett. 324:160–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Immonen A, Vapalahti M, Tyynelä K,
Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N and
Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous
ganciclovir improves survival in human malignant glioma: A
randomised, controlled study. Mol Ther. 10:967–972. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rainov NG: A phase III clinical evaluation
of herpes simplex virus type 1 thymidine kinase and ganciclovir
gene therapy as an adjuvant to surgical resection and radiation in
adults with previously untreated glioblastoma multiforme. Hum Gene
Ther. 11:2389–2401. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sangro B, Mazzolini G, Ruiz M, Ruiz J,
Quiroga J, Herrero I, Qian C, Benito A, Larrache J, Olagüe C, et
al: A phase I clinical trial of thymidine kinase-based gene therapy
in advanced hepatocellular carcinoma. Cancer Gene Ther. 17:837–843.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Voges J, Reszka R, Gossmann A, Dittmar C,
Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, et
al: Imaging-guided convection-enhanced delivery and gene therapy of
glioblastoma. Ann Neurol. 54:479–487. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moolten FL: Tumor chemosensitivity
conferred by inserted herpes thymidine kinase genes: Paradigm for a
prospective cancer control strategy. Cancer Res. 46:5276–5281.
1986.PubMed/NCBI
|
|
7
|
Wei SJ, Chao Y, Hung YM, Lin WC, Yang DM,
Shih YL, Ch'ang LY, Whang-Peng J and Yang WK: S- and G2-phase cell
cycle arrests and apoptosis induced by ganciclovir in murine
melanoma cells transduced with herpes simplex virus thymidine
kinase. Exp Cell Res. 241:66–75. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mesnil M and Yamasaki H: Bystander effect
in herpes simplex virus-thymidine kinase/ganciclovir cancer gene
therapy: Role of gap-junctional intercellular communication. Cancer
Res. 60:3989–3999. 2000.PubMed/NCBI
|
|
9
|
Bjornsti MA and Houghton PJ: The TOR
pathway: A target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Q, Thoreen C, Wang J, Sabatini D and
Gray NS: mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov
Today Ther Strateg. 6:47–55. 2009. View Article : Google Scholar
|
|
11
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar
|
|
12
|
Cornu M, Albert V and Hall MN: mTOR in
aging, metabolism, and cancer. Curr Opin Genet Dev. 23:53–62. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faivre S, Kroemer G and Raymond E: Current
development of mTOR inhibitors as anticancer agents. Nat Rev Drug
Discov. 5:671–688. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fasolo A and Sessa C: Current and future
directions in mammalian target of rapamycin inhibitors development.
Expert Opin Investig Drugs. 20:381–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue
P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways
by rapamycin-mediated mammalian target of rapamycin inhibition.
Cancer Res. 65:7052–7058. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hermonat PL and Muzyczka N: Use of
adeno-associated virus as a mammalian DNA cloning vector:
Transduction of neomycin resistance into mammalian tissue culture
cells. Proc Natl Acad Sci USA. 81:6466–6470. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park K, Kim WJ, Cho YH, Lee YI, Lee H,
Jeong S, Cho ES, Chang SI, Moon SK, Kang BS, et al: Cancer gene
therapy using adeno-associated virus vectors. Front Biosci.
13:2653–2659. 2008. View
Article : Google Scholar
|
|
19
|
Ahn J, Woo HN, Ko A, Khim M, Kim C, Park
NH, Song HY, Kim SW and Lee H: Multispecies-compatible antitumor
effects of a cross-species small-interfering RNA against mammalian
target of rapamycin. Cell Mol Life Sci. 69:3147–3158. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JY, Kim JH, Khim M, Lee HS, Jung JH,
Moon DH, Jeong S and Lee H: Persistent anti-tumor effects via
recombinant adeno-associated virus encoding herpes thymidine kinase
gene monitored by PET-imaging. Oncol Rep. 25:1263–1269.
2011.PubMed/NCBI
|
|
21
|
Shin O, Kim SJ, Lee WI, Kim JY and Lee H:
Effective transduction by self-complementary adeno-associated
viruses of human dendritic cells with no alteration of their
natural characteristics. J Gene Med. 10:762–769. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Black ME, Kokoris MS and Sabo P: Herpes
simplex virus-1 thymidine kinase mutants created by semi-random
sequence mutagenesis improve prodrug-mediated tumor cell killing.
Cancer Res. 61:3022–3026. 2001.PubMed/NCBI
|
|
23
|
Lee HS, Ahn J, Jun EJ, Yang S, Joo CH, Kim
YK and Lee H: A novel program to design siRNAs simultaneously
effective to highly variable virus genomes. Biochem Biophys Res
Commun. 384:431–435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmelzle T and Hall MN: TOR, a central
controller of cell growth. Cell. 103:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Black ME, Newcomb TG, Wilson HM and Loeb
LA: Creation of drug-specific herpes simplex virus type 1 thymidine
kinase mutants for gene therapy. Proc Natl Acad Sci USA.
93:3525–3529. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park SY, Lee W, Lee J and Kim IS:
Combination gene therapy using multidrug resistance (MDR1) gene
shRNA and herpes simplex virus-thymidine kinase. Cancer Lett.
261:205–214. 2008. View Article : Google Scholar
|
|
27
|
Bartholomeusz C and Gonzalez-Angulo AM:
Targeting the PI3K signaling pathway in cancer therapy. Expert Opin
Ther Targets. 16:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grabiner BC, Nardi V, Birsoy K, Possemato
R, Shen K, Sinha S, Jordan A, Beck AH and Sabatini DM: A diverse
array of cancer-associated MTOR mutations are hyperactivating and
can predict rapamycin sensitivity. Cancer Discov. 4:554–563. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mingozzi F and High KA: Therapeutic in
vivo gene transfer for genetic disease using AAV: Progress and
challenges. Nat Rev Genet. 12:341–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mueller C and Flotte TR: Clinical gene
therapy using recombinant adeno-associated virus vectors. Gene
Ther. 15:858–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ylä-Herttuala S: Endgame: Glybera finally
recommended for approval as the first gene therapy drug in the
European union. Mol Ther. 20:1831–1832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim SJ, Lee WI, Heo H, Shin O, Kwon YK and
Lee H: Stable gene expression by self-complementary
adeno-associated viruses in human MSCs. Biochem Biophys Res Commun.
360:573–579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SJ, Lee WI, Lee YS, Kim DH, Chang JW,
Kim SW and Lee H: Effective relief of neuropathic pain by
adeno-associated virus-mediated expression of a small hairpin RNA
against GTP cyclohydrolase 1. Mol Pain. 5:672009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HS, Shin OK, Kim SJ, Lee WI, Jeong S,
Park K, Choe H and Lee H: Efficient gene expression by
self-complementary adeno-associated virus serotype 2 and 5 in
various human cancer cells. Oncol Rep. 18:611–616. 2007.PubMed/NCBI
|
